Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor

Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor

The development of new systemic agents has led us into a “golden era” of management of metastatic renal cell carcinoma (RCC). Certainly, the approval of immune-checkpoint inhibitors and the combination of these with targeted compounds has irreversibly changed clinical scenarios....

Full description

Bibliographic Details
Main Authors: Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Marina Scarpelli, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Rodolfo Montironi, Francesco Massari
Format: Article
Language:English
Published: MDPI AG 2019-06-01
Series:Cancers
Subjects:
renal cell carcinoma
VEGFR
VEGF
mTOR
PD-1/PD-L1
immune-checkpoint inhibitors
target therapy
primary resistance
acquired resistance
predictive markers
Online Access:https://www.mdpi.com/2072-6694/11/6/830

Internet

https://www.mdpi.com/2072-6694/11/6/830

Similar Items